rapt logo
  • About
    • Who We Are
    • Leadership Team
    • Board of Directors
    • Clinical and Scientific Advisors
    • Contact
  • Science
    • Immune Continuum
    • Immunoglobulin E (IgE) in Allergic Conditions
    • CCR4 in Inflammation
  • Pipeline
    • Snapshot
    • RPT904
  • Investors
    • Corporate Profile
    • Press Releases
    • Events and Presentations
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Email Alerts
    • Investor Contact
    • Investor FAQs
  • Careers
    • Culture
    • Benefits
    • Open Positions

PRESS RELEASES

Year
October 27 | 2025
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
October 21 | 2025
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
October 21 | 2025
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
October 20 | 2025
RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria
October 19 | 2025
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
September 29 | 2025
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
August 27 | 2025
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
August 07 | 2025
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
June 23 | 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
June 13 | 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Contact Us
+1.650.489.9000
inquiries@rapt.com
  • Linked In account
  • Youtube account
rapt-logo.png
  • Home
  • About
  • Science
  • Pipeline
  • Careers
  • Terms Of Use
  • Privacy Policy
  • Linked In account
  • Youtube account

© 2025 RAPT Therapeutics, Inc.
All rights reserved.

You are leaving RAPT.com to go to the eczema clinical trial study site.
YES